The news that Virpax Pharmaceuticals' product, Envelta, is on track for human trials following an FDA review is a positive development for the company. It suggests that the FDA has not found any significant issues that would delay the trial process, indicating progress in the development of their product. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.